CR9064A - Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso - Google Patents

Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso

Info

Publication number
CR9064A
CR9064A CR9064A CR9064A CR9064A CR 9064 A CR9064 A CR 9064A CR 9064 A CR9064 A CR 9064A CR 9064 A CR9064 A CR 9064A CR 9064 A CR9064 A CR 9064A
Authority
CR
Costa Rica
Prior art keywords
bone
cancer
tumors
types
treatment
Prior art date
Application number
CR9064A
Other languages
English (en)
Inventor
Jens Hoffmann
Ulrich Klar
Hubertus Pietsch
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9064(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR9064A publication Critical patent/CR9064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invencion se refiere al uso de epotilonas en el tratamiento de metastasis en el hueso y tumores o tipos de cancer en hueso, mas en particular para tratar, prevenir o aliviar las metastasis en un paciente de cancer.
CR9064A 2004-09-24 2007-04-19 Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso CR9064A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090377A EP1640004A1 (en) 2004-09-24 2004-09-24 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Publications (1)

Publication Number Publication Date
CR9064A true CR9064A (es) 2007-10-01

Family

ID=34928830

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9064A CR9064A (es) 2004-09-24 2007-04-19 Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso

Country Status (21)

Country Link
EP (2) EP1640004A1 (es)
JP (1) JP2008514569A (es)
KR (1) KR20070054214A (es)
CN (1) CN101065126A (es)
AR (1) AR051035A1 (es)
AU (1) AU2005287477A1 (es)
BR (1) BRPI0516080A (es)
CA (1) CA2580215A1 (es)
CR (1) CR9064A (es)
EC (1) ECSP077390A (es)
GT (1) GT200500267A (es)
IL (1) IL181785A0 (es)
MX (1) MX2007003503A (es)
NO (1) NO20072099L (es)
PA (1) PA8646201A1 (es)
PE (1) PE20060695A1 (es)
RU (1) RU2007115162A (es)
TW (1) TW200626150A (es)
UY (1) UY29136A1 (es)
WO (1) WO2006032537A2 (es)
ZA (1) ZA200703306B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930004A1 (en) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Use of epothilones in the treatment of osteoporosis and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
BR9916833A (pt) * 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
PE20010116A1 (es) * 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
HK1049787B (en) * 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004508810A (ja) * 2000-04-28 2004-03-25 コーサン　バイオサイエンシーズ，　インコーポレイテッド ポリケチドの生成
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
WO2002080846A2 (en) * 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
KR20040106422A (ko) * 2002-05-01 2004-12-17 노파르티스 아게 간암 및 다른 암 질병 치료용 에포틸론 유도체
JP2006510626A (ja) * 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
WO2005000292A1 (en) * 2003-06-27 2005-01-06 Novartis Ag Cancer treatment with epothilones
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
ECSP077390A (es) 2007-05-30
IL181785A0 (en) 2007-07-04
PE20060695A1 (es) 2006-08-03
KR20070054214A (ko) 2007-05-28
CA2580215A1 (en) 2006-03-30
GT200500267A (es) 2006-06-06
JP2008514569A (ja) 2008-05-08
TW200626150A (en) 2006-08-01
WO2006032537A2 (en) 2006-03-30
PA8646201A1 (es) 2006-11-09
ZA200703306B (en) 2010-06-30
EP1809281A2 (en) 2007-07-25
RU2007115162A (ru) 2008-11-20
CN101065126A (zh) 2007-10-31
AR051035A1 (es) 2006-12-13
EP1640004A1 (en) 2006-03-29
UY29136A1 (es) 2006-04-28
WO2006032537A3 (en) 2006-05-04
BRPI0516080A (pt) 2008-08-19
AU2005287477A1 (en) 2006-03-30
NO20072099L (no) 2007-04-23
MX2007003503A (es) 2007-08-17

Similar Documents

Publication Publication Date Title
MX2007014132A (es) Compuestos de diarilhidantoina.
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
PL2100618T3 (pl) Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
UY31484A1 (es) Piperidinas heteroaril-sustituidas
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
TW200509892A (en) Novel aminobenzophenone compounds
CO6781549A2 (es) Uso de ligandos sigma en dolor por cáncer de huesos
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
NO20081292L (no) Pentasykliske kinaseinhibitorer
SE0301650D0 (sv) Novel compounds
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
EP1789064A4 (en) ENHANCED ANTICANCER TREATMENT
NO20053903D0 (no) Nukleotidlipidesterderivater.
CR9064A (es) Uso de epotilonas en el tratamiento de metastasis en hueso y tumores o tipos de cancer en hueso
ATE399532T1 (de) Medizinische seife
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
TW200628168A (en) Use of organic compounds
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
EP1654537A4 (en) TSSK4: A HUMAN TESTISS-SPECIFIC SERIN / THREONIN KINASE
TW200616659A (en) Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-included pain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)